IBD Medication Calendar: Infusions, Injections, Labs, Refills, and Prior-Authorization Dates

Treatment for inflammatory bowel disease, meaning Crohn's disease and ulcerative colitis, runs on more schedules than most people expect. An infusion appointment sits on one interval, a self-injected biologic on another, blood work on a third, and pharmacy refills and insurance paperwork on schedules nobody prints on a label at all. The National Institute of Diabetes and Digestive and Kidney Diseases groups IBD therapy into corticosteroids, immunosuppressants, biologics, and small molecule medicines, and each category carries its own timing demands. An IBD medication calendar that captures every one of these date types, rather than dose reminders alone, is what keeps a treatment plan from developing quiet gaps.

Why Dose Reminders Alone Are Not Enough

Missing doses has measurable consequences. In a study of patients with quiescent ulcerative colitis, those who refilled less than 80% of prescribed doses had more than a fivefold greater risk of recurrence than adherent patients over 12 months. That risk is the reason most people start using reminders in the first place.

The problem is that a missed dose is often the last event in a chain that started weeks earlier. A refill was not requested in time, a prior authorization expired, a required lab was never drawn, or an infusion center could not find an opening on the right week. A calendar built only around "take medication today" gives no warning about any of those upstream steps. A calendar built around the full set of treatment events gives you several weeks of lead time on each one.

Mapping Infusion and Injection Dates

Start by writing down the actual schedule from your drug's prescribing information, not an approximation. Induction schedules are front-loaded and irregular, and they are where people most often lose track.

Infliximab is dosed at 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks for both Crohn's disease and ulcerative colitis. Vedolizumab follows 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter, with a subcutaneous maintenance option of 108 mg every 2 weeks starting at week 6. Ustekinumab uses a single weight-based intravenous dose followed by 90 mg subcutaneously 8 weeks later, then every 8 weeks. Risankizumab uses intravenous induction at weeks 0, 4, and 8, then 180 mg or 360 mg subcutaneously at week 12 and every 8 weeks after. Adalimumab starts at 160 mg on day 1, 80 mg on day 15, then 40 mg every other week from day 29.

Enter every one of those dates individually through at least the first year rather than relying on a repeating rule, because induction weeks break the pattern. For infusions, add a second entry roughly six weeks ahead of each appointment labeled as the scheduling window, since that is when infusion centers still have flexible slots.

Lab Draws Belong on the Same Calendar

Blood work is the item most often left off a medication calendar, and it is frequently the item that blocks the next dose. Thiopurines require dense early monitoring: the azathioprine label calls for complete blood counts weekly during the first month, twice monthly for months two and three, then monthly or more often after dose changes. Tofacitinib carries its own schedule, with the label directing clinicians to monitor lymphocyte counts at baseline and every 3 months, neutrophils and hemoglobin at baseline, at 4 to 8 weeks, and every 3 months, and lipids at 4 to 8 weeks after starting.

Drug level testing is a separate category again. The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adults with active IBD on anti-tumor necrosis factor agents, and makes no recommendation on routine proactive monitoring during remission. Reactive testing is not calendar-driven, so instead of scheduling it, note on your calendar which labs your team ordered and when, so that a trough level can be drawn at the correct point before a dose rather than after.

Refill Windows and Prior-Authorization Renewals

Refill and authorization dates deserve the same treatment as clinical dates, because insurance timing produces real treatment delays. In a two-site analysis of patients starting advanced IBD therapies, only 46.6% received a first dose within 14 days, and insurance denial raised the odds of delay 2.72-fold while intravenous administration raised them 3.07-fold. Renewals were affected too, with intravenous medications delayed in 71.9% of maintenance renewal cases. A study of payor barriers in pediatric IBD found a median 18-day delay to receiving the prescribed medication, 60% of patients experiencing an adverse outcome, and 21% requiring hospitalization, even though 77% of initial denials were eventually approved.

Those numbers argue for early, calendared action rather than reacting when a pharmacy says no. Three entries cover most of it:

• A refill request reminder set 10 to 14 days before your current supply runs out, not on the day it does
• A prior-authorization expiration date, with a separate alert 60 days earlier to begin renewal paperwork
• An insurance plan year start date, since formularies, specialty pharmacy contracts, and deductibles reset then

Setting Up the Workflow

Build the calendar once with four color-coded categories: infusions and injections, labs, refills, and authorizations. Give every entry a title that states the action and the drug, then add two alerts to each, one a day ahead and one far enough ahead to actually fix a problem. For infusions that means weeks, for refills days.

Keep a running note attached to the calendar recording what was administered, on what date, at what dose, and which labs were drawn. That record answers the questions a gastroenterology team asks at every visit, and it also creates the paper trail needed for an appeal when an authorization lapses. Review the whole calendar once a quarter, since dose escalation, a drug switch, or a change in insurance can shift every downstream date at once.

A medication calendar built this way is a logistics document as much as a clinical one. The doses, the blood draws, the pharmacy requests, and the insurance renewals all have to line up for treatment to continue uninterrupted, and the failure of any single one of them tends to surface only when the next dose is already overdue.